AUMED is preparing the production of a mass-produced medical product. Under the contract manufacturing regime, AUMED wants to become a manufacturer of the STAFAL medicine, which, on the basis of bacteriophage, as an active substance, addresses one of the possible alternative ways to combat the growing resistance to antibiotics. STAFAL is a unique authorized product in the EU. The safety and effectiveness of the medicine is validated by many years of use in the medical field.
With this step, the company significantly expands its portfolio of professional activities in the field of human immunobiological issues, which is one of its thematic priorities.
AUMED has received support for the project titled “Development of an Immunization Product for Protection Against the Causative Agent of…
AUMED has received support for the project “Innovation in the Production of Immunological Preparations,” registration number CZ.01.01.01/02/24_051/0004982. The essence of…
Our subsidiary, AUMED Pharma a.s., is expanding the Phage Glow range with two new product lines: ATOPCARE Atopcare is here…
Research projects of Aumed, a.s. are financed by the European Structural Funds and with financial support from the state budget through the Ministry of Industry and Trade. A complete list of all ongoing and completed projects with this support can be found here.
Ministry of Industry and Trade
Program TRIO
European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness
Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s
